Peroxisome Proliferator-Activated Receptor γ as a Novel Therapeutic Target in Asthma

References

• Bousquet J, Jeffery P K, Busse W W, Johnson M, Vignola A M. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161: 1720–1745
   PubMed Web of Science ®Google Scholar
• Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645–650
   PubMed Web of Science ®Google Scholar
• Wahli W, Braissant O, Desvergne B. Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more. Chem Biol 1995; 2: 261–266
   PubMed Web of Science ®Google Scholar
• Blanquart C, Barbier O, Fruchart J C, Staels B, Glineur C. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol 2003; 85: 267–273
   PubMed Web of Science ®Google Scholar
• Na H K, Surh Y J. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation. Biochem Pharmacol 2003; 66: 1381–1391
   PubMed Web of Science ®Google Scholar
• Chinetti G, Griglio S, Antonucci M, Torra I P, Delerive P, Majd Z, Fruchart J C, Chapman J, Najib J, Staels B. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998; 273: 25573–25580
   PubMed Web of Science ®Google Scholar
• Gelman L, Fruchart J C, Auwerx J. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci 1999; 55: 932–943
   PubMed Web of Science ®Google Scholar
• Jiang C, Ting A T, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82–86
   PubMed Web of Science ®Google Scholar
• Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992; 68: 879–887
   PubMed Web of Science ®Google Scholar
• Hotta K, Gustafson T A, Yoshioka S, Ortmeyer H K, Bodkin N L, Hansen B C. Relationships of PPARgamma and PPARgamma2 mRNA levels to obesity, diabetes and hyperinsulinaemia in rhesus monkeys. Int J Obes Relat Metab Disord 1998; 22: 1000–1010
   PubMedGoogle Scholar
• Houseknecht K L, Bidwell C A, Portocarrero C P, Spurlock M E. Expression and cDNA cloning of porcine peroxisome proliferator-activated receptor gamma (PPARgamma). Gene 1998; 225: 89–96
   PubMed Web of Science ®Google Scholar
• Greene M E, Blumberg B, McBride O W, Yi H F, Kronquist K, Kwan K, Hsieh L, Greene G, Nimer S D. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr 1995; 4: 281–299
   PubMedGoogle Scholar
• Zhu Y, Qi C, Korenberg J R, Chen X N, Noya D, Rao M S, Reddy J K. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc Natl Acad Sci U S A 1995; 92: 7921–7925
   PubMed Web of Science ®Google Scholar
• Abdelrahman M, Sivarajah A, Thiemermann C. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res 2005; 65: 772–781
   PubMed Web of Science ®Google Scholar
• Fajas L, Fruchart J C, Auwerx J. PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett 1998; 438: 55–60
   PubMed Web of Science ®Google Scholar
• Ricote M, Li A C, Willson T M, Kelly C J, Glass C K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79–82
   PubMed Web of Science ®Google Scholar
• Ren D, Collingwood T N, Rebar E J, Wolffe A P, Camp H S. PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev 2002; 16: 27–32
   PubMed Web of Science ®Google Scholar
• Mueller E, Drori S, Aiyer A, Yie J, Sarraf P, Chen H, Hauser S, Rosen E D, Ge K, Roeder R G, Spiegelman B M. Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms. J Biol Chem 2002; 277: 41925–41930
   PubMed Web of Science ®Google Scholar
• Patel H J, Belvisi M G, Bishop-Bailey D, Yacoub M H, Mitchell J A. Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy. J Immunol 2003; 170: 2663–2669
   PubMedGoogle Scholar
• Denning G M, Stoll L L. Peroxisome proliferator-activated receptors: potential therapeutic targets in lung disease?. Pediatr Pulmonol 2006; 41: 23–34
   PubMedGoogle Scholar
• Pawliczak R, Han C, Huang X L, Demetris A J, Shelhamer J H, Wu T. 85-kDa cytosolic phospholipase A2 mediates peroxisome proliferator-activated receptor gamma activation in human lung epithelial cells. J Biol Chem 2002; 277: 33153–33163
   PubMed Web of Science ®Google Scholar
• Adams M, Montague C T, Prins J B, Holder J C, Smith S A, Sanders L, Digby J E, Sewter C P, Lazar M A, Chatterjee V K, O'Rahilly S. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100: 3149–3153
   PubMed Web of Science ®Google Scholar
• Kliewer S A, Umesono K, Noonan D J, Heyman R A, Evans R M. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992; 358: 771–774
   PubMed Web of Science ®Google Scholar
• Berger J, Moller D E. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409–435
   PubMed Web of Science ®Google Scholar
• Xu H E, Lambert M H, Montana V G, Parks D J, Blanchard S G, Brown P J, Sternbach D D, Lehmann J M, Wisely G B, Willson T M, Kliewer S A, Milburn M V. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 1999; 3: 397–403
   PubMed Web of Science ®Google Scholar
• Nagy L, Tontonoz P, Alvarez J G, Chen H, Evans R M. Oxidized L DL regulates macrophage gene expression through ligand activation of PPARgamma. Cell, 1998; 93: 229–240
   PubMed Web of Science ®Google Scholar
• Willson T M, Brown P J, Sternbach D D, Henke B R. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43: 527–550
   PubMed Web of Science ®Google Scholar
• Forman B M, Tontonoz P, Chen J, Brun R P, Spiegelman B M, Evans R M. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995; 83: 803–812
   PubMed Web of Science ®Google Scholar
• Boyault S, Bianchi A, Moulin D, Morin S, Francois M, Netter P, Terlain B, Bordji K. 15-Deoxy-delta(12,14)-prostaglandin J(2) inhibits IL-1beta-induced IKK enzymatic activity and IkappaBalpha degradation in rat chondrocytes through a PPARgamma-independent pathway. FEBS Lett 2004; 572: 33–40
   PubMed Web of Science ®Google Scholar
• Ibrahimi A, Teboul L, Gaillard D, Amri E Z, Ailhaud G, Young P, Cawthorne M A, Grimaldi P A. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol Pharmacol 1994; 46: 1070–1076
   PubMed Web of Science ®Google Scholar
• Henke B R. Peroxisome proliferator-activated receptor gamma (PPAR gamma) ligands and their therapeutic utility. Prog Med Chem 2004; 42: 1–53
   PubMedGoogle Scholar
• Sohda T, Mizuno K, Momose Y, Ikeda H, Fujita T, Meguro K. Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents. J Med Chem 1992; 35: 2617–2626
   PubMed Web of Science ®Google Scholar
• Narce M, Poisson J P. Novel PPARgamma-dependent and independent effects for thiazolidinediones. Curr Opin Lipidol 2003; 14: 651–652
   PubMedGoogle Scholar
• Cho D H, Choi Y J, Jo S A, Jo I. Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-independent signaling pathways. J Biol Chem 2004; 279: 2499–2506
   PubMed Web of Science ®Google Scholar
• Hilding A, Hall K, Skogsberg J, Ehrenborg E, Lewitt M S. Troglitazone stimulates IGF-binding protein-1 by a PPAR gamma-independent mechanism. Biochem Biophys Res Commun 2003; 303: 693–699
   PubMed Web of Science ®Google Scholar
• Chen F, Wang M, O'Connor J P, He M, Tripathi T, Harrison L E. Phosphorylation of PPARgamma via active ERK1/2 leads to its physical association with p65 and inhibition of NF-kappabeta. J Cell Biochem 2003; 90: 732–744
   PubMed Web of Science ®Google Scholar
• Pershadsingh H A. Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?. Expert Opin Investig Drugs 2004; 13: 215–228
   PubMed Web of Science ®Google Scholar
• Knouff C, Auwerx J. Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 2004; 25: 899–918
   PubMed Web of Science ®Google Scholar
• Berger J, Tanen M, Elbrecht A, Hermanowski-Vosatka A, Moller D E, Wright S D, Thieringer R. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity. J Biol Chem 2001; 276: 12629–12635
   PubMedGoogle Scholar
• Berger J P, Petro A E, Macnaul K L, Kelly L J, Zhang B B, Richards K, Elbrecht A, Johnson B A, Zhou G, Doebber T W, Biswas C, Parikh M, Sharma N, Tanen M R, Thompson G M, Ventre J, Adams A D, Mosley R, Surwit R S, Moller D E. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol 2003; 17: 662–676
   PubMed Web of Science ®Google Scholar
• Acton J J, 3rd, Black R M, Jones A B, Moller D E, Colwell L, Doebber T W, Macnaul K L, Berger J, Wood H B. Benzoyl 2-methyl indoles as selective PPARgamma modulators. Bioorg Med Chem Lett 2005; 15: 357–362
   PubMed Web of Science ®Google Scholar
• Minoura H, Takeshita S, Ita M, Hirosumi J, Mabuchi M, Kawamura I, Nakajima S, Nakayama O, Kayakiri H, Oku T, Ohkubo-Suzuki A, Fukagawa M, Kojo H, Hanioka K, Yamasaki N, Imoto T, Kobayashi Y, Mutoh S. Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. Eur J Pharmacol 2004; 494: 273–281
   PubMed Web of Science ®Google Scholar
• Chinetti G, Griglio S, Antonucci M, Torra I P, Delerive P, Majd Z, Fruchart J C, Chapman J, Najib J, Staels B. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998; 273: 25573–25580
   PubMed Web of Science ®Google Scholar
• Theocharisa S, Margeli A, Kouraklis G. Peroxisome proliferator activated receptor-gamma ligands as potent antineoplastic agents. Curr Med Chem Anti-Canc Agents 2003; 3: 239–251
   PubMedGoogle Scholar
• Kostadinova R, Wahli W, Michalik L. PPARs in diseases: control mechanisms of inflammation. Curr Med Chem 2005; 12: 2995–3009
   PubMed Web of Science ®Google Scholar
• Alarcon de la Lastra C, Sanchez-Fidalgo S, Villegas I, Motilva V. New pharmacological perspectives and therapeutic potential of PPAR-gamma agonists. Curr Pharm Des 2004; 10: 3505–3524
   PubMed Web of Science ®Google Scholar
• Busse W W, Lemanske R F, Jr. Asthma. N Engl J Med 2001; 344: 350–362
   PubMed Web of Science ®Google Scholar
• Humbles A A, Lloyd C M, McMillan S J, Friend D S, Xanthou G, McKenna E E, Ghiran S, Gerard N P, Yu C, Orkin S H, Gerard C. A critical role for eosinophils in allergic airways remodeling. Science 2004; 305: 1776–1779
   PubMed Web of Science ®Google Scholar
• Lee J J, Dimina D, Macias M P, Ochkur S I, McGarry M P, O'Neill K R, Protheroe C, Pero R, Nguyen T, Cormier S A, Lenkiewicz E, Colbert D, Rinaldi L, Ackerman S J, Irvin C G, Lee N A. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 2004; 305: 1773–1776
   PubMed Web of Science ®Google Scholar
• Wang A C, Dai X, Luu B, Conrad D J. Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. Am J Respir Cell Mol Biol 2001; 24: 688–693
   PubMed Web of Science ®Google Scholar
• Benayoun L, Letuve S, Druilhe A, Boczkowski J, Dombret M C, Mechighel P, Megret J, Leseche G, Aubier M, Pretolani M. Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling. Am J Respir Crit Care Med 2001; 164: 1487–1494
   PubMed Web of Science ®Google Scholar
• Woerly G, Honda K, Loyens M, Papin J P, Auwerx J, Staels B, Capron M, Dombrowicz D. Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J Exp Med 2003; 198: 411–421
   PubMed Web of Science ®Google Scholar
• Honda K, Marquillies P, Capron M, Dombrowicz D. Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model. J Allergy Clin Immunol 2004; 113: 882–888
   PubMed Web of Science ®Google Scholar
• Trifilieff A, Bench A, Hanley M, Bayley D, Campbell E, Whittaker P. PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effect. Br J Pharmacol 2003; 139: 163–171
   PubMedGoogle Scholar
• Mueller C, Weaver V, Vanden Heuvel J P, August A, Cantorna M T. Peroxisome proliferator-activated receptor gamma ligands attenuate immunological symptoms of experimental allergic asthma. Arch Biochem Biophys 2003; 418: 186–196
   PubMedGoogle Scholar
• Hammad H, de Heer H J, Soullie T, Angeli V, Trottein F, Hoogsteden H C, Lambrecht B N. Activation of peroxisome proliferator-activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma. Am J Pathol 2004; 164: 263–271
   PubMed Web of Science ®Google Scholar
• Lee K S, Park S J, Hwang P H, Yi H K, Song C H, Chai O H, Kim J S, Lee M K, Lee Y C. PPAR-gamma modulates allergic inflammation through up-regulation of PTEN. FASEB J 2005; 19: 1033–1035
   PubMedGoogle Scholar
• Kim S R, Lee K S, Park H S, Park S J, Min K H, Jin S M, Lee Y C. Involvement of IL-10 in peroxisome proliferator-activated receptor gamma-mediated anti-inflammatory response in asthma. Mol Pharmacol 2005; 68: 1568–1575
   PubMedGoogle Scholar
• Lee K S, Kim S R, Park S J, Park H S, Min K H, Jin S M, Lee M K, Kim U H, Lee Y C. PPARγ modulates reactive oxygen species generation and activation of NF-κB and HIF-1α in allergic airway disease of mice. J Allergy Clin Immunol 2006; 118: 120–127
   PubMed Web of Science ®Google Scholar
• Sugiyama H, Nonaka T, Kishimoto T, Komoriya K, Tsuji K, Nakahata T. Peroxisome proliferator-activated receptors are expressed in human cultured mast cells: a possible role of these receptors in negative regulation of mast cell activation. Eur J Immunol 2000; 30: 3363–3370
   PubMed Web of Science ®Google Scholar
• Nie M, Corbett L, Knox A J, Pang L. Differential regulation of chemokine expression by peroxisome proliferator-activated receptor gamma agonists: interactions with glucocorticoids and beta2-agonists. J Biol Chem 2005; 280: 2550–2561
   PubMedGoogle Scholar
• Hoshino M, Takahashi M, Takai Y, Sim J. Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J Allergy Clin Immunol 1999; 104: 356–363
   PubMed Web of Science ®Google Scholar
• Simpson J L, Scott R J, Boyle M J, Gibson P G. Differential proteolytic enzyme activity in eosinophilic and neutrophilic asthma. Am J Respir Crit Care Med 2005; 172: 559–565
   PubMed Web of Science ®Google Scholar
• Hetzel M, Walcher D, Grub M, Bach H, Hombach V, Marx N. Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells. Thorax 2003; 58: 778–783
   PubMed Web of Science ®Google Scholar
• Patel L, Pass I, Coxon P, Downes C P, Smith S A, Macphee C H. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol 2001; 11: 764–768
   PubMed Web of Science ®Google Scholar
• Dworski R. Oxidant stress in asthma. Thorax 2000; 55: S51–53
   PubMed Web of Science ®Google Scholar
• Villegas I, Martin A R, Toma W, de la Lastra C A. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation. Eur J Pharmacol 2004; 28: 195–203
   Google Scholar
• Mehta J L, Hu B, Chen J, Li D. Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation. Arterioscler Thromb Vasc Biol 2003; 23: 2203–2208
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Nakahara K. Improvement of asthma after administration of pioglitazone. Diabetes Care 2002; 25: 401
   PubMed Web of Science ®Google Scholar